

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

February 27, 2023

To Shareholders

Company Name: Renascience Inc

Corporation Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

Inquiries: Hiroyasu Ishimaru, Corporate Officer, in charge of
Administration and Corporate Planning

Notice of Adoption of AMED Research on Development of New Medical Devices

The Company is pleased to announce that “Development of Software as Medical Device Supporting Optimal Dehydration in Hemodialysis Therapy” project by Tohoku University, the collaborator of the Company, is adopted in the Research on Development of New Medical Devices by Japan Agency for Medical Research and Development (AMED) in FY2023.

Particulars

1. Adopted Project

Name of Program: Research on Development of New Medical Devices in FY2023

Name of Project: Development of Software as Medical Device Supporting Optimal Dehydration in Hemodialysis Therapy (*1)

In this project, Tohoku University will receive a research grant from AMED to develop software as a medical device to support optimal dehydration in hemodialysis therapy in collaboration with University of Tokyo, St. Luke's International Hospital, Central Hospital of the National Center for Global Health and Medicine, and several private dialysis treatment institutions. Tohoku University (the representative research institute of the project) and the company signed the "Collaboration Agreement on Research for Medical Solution through Open Innovation" on December 16, 2021, and have been developing this software as a medical device. In this project, we will improve the prediction accuracy of the artificial intelligence and verify its performance in the clinical study. As a research partner, the Company will provide Tohoku University with medical data and a proprietary AI engine (algorithm) jointly developed by NEC and the Company. The AI engine will be customized for medical use by learning medical data obtained from various medical institutions under the advice of nephrologists specialized for dialysis, and the clinical performance test will be conducted to apply for

approval, leading to practical use of the AI engine promptly after the project is completed.

2. Outlook for the future

There is no change in the forecast for the fiscal year ending March 31, 2023, as a result of this matter.

End

*1: About 350,000 hemodialysis patients in Japan undergo dehydration and waste removal to replace their crippled kidneys. Insufficient dehydration impairs cardiopulmonary function, while excessive dehydration causes hypotension during dialysis, resulting in adverse events such as mood disorders and loss of consciousness. Dialysis hospitals treat many patients with a small staff of one physician and several nurses and clinical engineers, and adverse events can place a heavy burden on the staff. Since this project will predict drop of blood pressure during dialysis for individual patients in real time and determine appropriate and safe dehydration volume, it will reduce the burden of medical personnel involved in dialysis treatment with few human resources, enable safe dialysis treatment, and solve important medical issues to improve the QOL and prognosis of dialysis patients.